tradingkey.logo

Harvard Bioscience Inc

HBIO
View Detailed Chart
0.589USD
-0.028-4.48%
Close 11/05, 16:00ETQuotes delayed by 15 min
26.22MMarket Cap
LossP/E TTM

Harvard Bioscience Inc

0.589
-0.028-4.48%
Intraday
1m
30m
1h
D
W
M
D

Today

-4.48%

5 Days

+31.85%

1 Month

+31.11%

6 Months

+78.45%

Year to Date

-72.10%

1 Year

-75.37%

View Detailed Chart

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Harvard Bioscience Inc's Score

Industry at a Glance

Industry Ranking
119 / 210
Overall Ranking
256 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
2.000
Target Price
+248.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Harvard Bioscience Inc Highlights

StrengthsRisks
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Growing
The company is in a growing phase, with the latest annual income totaling USD 94.14M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 94.14M.
Overvalued
The company’s latest PE is -0.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.11M shares, decreasing 25.58% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.85M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.72.

Harvard Bioscience Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Harvard Bioscience Inc Info

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Ticker SymbolHBIO
CompanyHarvard Bioscience Inc
CEOMr. John D. Duke
Websitehttps://www.harvardbioscience.com/
KeyAI